PubRank

Andrew J Ullmann

Author PubWeight™ 64.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 10.40
2 Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 5.15
3 Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014 3.12
4 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 3.11
5 Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007 2.10
6 Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 2004 1.98
7 Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010 1.91
8 Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 1.54
9 Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 1.38
10 Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005 1.24
11 Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2008 1.24
12 Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2008 1.17
13 Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 1.11
14 Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010 1.06
15 Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008 1.06
16 Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009 1.01
17 Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011 0.99
18 Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents 2009 0.98
19 Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008 0.98
20 A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007 0.97
21 Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013 0.96
22 Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2006 0.95
23 Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 0.94
24 Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013 0.93
25 Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008 0.92
26 Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report. Graefes Arch Clin Exp Ophthalmol 2004 0.89
27 Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009 0.88
28 Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opin Drug Saf 2011 0.88
29 An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2005 0.87
30 Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006 0.84
31 Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2007 0.84
32 Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses 2011 0.82
33 Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2002 0.81
34 Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012 0.81
35 Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002 0.81
36 Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 0.81
37 Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 2014 0.81
38 Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004 0.80
39 Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. Mycoses 2013 0.80
40 Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008 0.76
41 Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis 2005 0.76
42 [Opportunistic infections after treatment with monoclonal antibodies]. Wien Med Wochenschr 2004 0.76
43 Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004 0.75
44 Correspondence (letter to the editor): Particular characteristics of encapsulated bacteria. Dtsch Arztebl Int 2011 0.75
45 Is there a role for polyenes in treating invasive mycoses? Curr Opin Infect Dis 2006 0.75
46 Tool for guidance: evidence-based recommendations for managing febrile neutropenia. Korean J Intern Med 2011 0.75
47 Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw 2008 0.75
48 CMV prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014 0.75
49 Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005 0.75
50 A multidisciplinary approach to managing invasive fungal disease. Preface. J Antimicrob Chemother 2013 0.75
51 Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother 2017 0.75
52 Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality. Ann Hematol 2005 0.75
53 [Current development in the diagnostics and therapy of systemic fungal infections in cancer patients]. Wien Med Wochenschr 2004 0.75